Objective: To propose benchmark outcome values in liver transplantation, serving as reference for assessing individual patients or any other patient groups.
Background: Best achievable results in liver transplantation, that is, benchmarks, are unknown. Consequently, outcome comparisons within or across centers over time remain speculative. Methods: Out of 7492 liver transplantation performed in 17 international centers from 3 continents, we identified 2024 low risk adult cases with a laboratory model for end-stage liver disease score 20 points, a balance of risk score 9, and receiving a primary graft by donation after brain death. We chose clinically relevant endpoints covering intra-and postoperative course, with a focus on complications graded by severity including the complication comprehensive index (CCI 1 ). Respective benchmarks were derived from the median value in each center, and the 75 percentile was considered the benchmark cutoff. Results: Benchmark cases represented 8% to 49% of cases per center. Oneyear patient-survival was 91.6% with 3.5% retransplantations. Eighty-two percent of patients developed at least 1 complication during 1-year follow-up. Biliary complications occurred in one-fifth of the patients up to 6 months after surgery. Benchmark cutoffs were 4 days for ICU stay, 18 days for hospital stay, 59% for patients with severe complications (! Grade III) and 42.1 for 1-year CCI 1 . Comparisons with the next higher risk group (model for end stage liver disease 21-30) disclosed an increase in morbidity but within benchmark cutoffs for most, but not all indicators, while in patients receiving a second graft from 1 center (n ¼ 50) outcome values were all outside of benchmark values. Conclusions: Despite excellent 1-year survival, morbidity in benchmark cases remains high with half of patients developing severe complications during 1-year follow-up. Benchmark cutoffs targeting morbidity parameters offer a valid tool to assess higher risk groups.
Keywords: benchmark, complication, liver transplantation, morbidity, outcome (Ann Surg 2018;267:419-425) M ore than 300.000 liver transplantations (LT) have been performed worldwide, since its introduction in clinical practice in the early 1980s. [1] [2] [3] With major improvements in surgical techniques, immunosuppression therapy, and patient selection 1-year patient survival rates have continuously improved to over 85%. 2,4 -6 LT is
From the currently the standard of care for many patients with end-stage liver disease and liver tumors; a success that has created a dramatic imbalance between organ need and availability. 7, 8 To face the resultant organ shortage, higher-risk grafts are implanted in sick recipients, potentially jeopardizing the postoperative course. One of the main issues in evaluating the results of LT is the lack of reliable comparison to reference groups.
With this in mind, we embarked on the concept of benchmarking, which is widely known as quality assessment and improvement in the field of banking or industrial manufacturing. Benchmarking has been used in medicine as a tool for evaluating single-center outcomes by risk-adjusted comparisons to national data. [9] [10] [11] We introduced the idea of identifying best achievable results by selecting low risk cases in experienced centers and presented a large multicenter study at the American Surgical Association annual meeting in 2016, proposing benchmark values for major hepatectomies. The ideal low risk cases were those performed in healthy living-donor using a comprehensive analysis of relevant endpoints. 12 To define benchmark values in LT, we targeted high-volume programs, holding an audited prospective database from areas, where cadaveric LT is common practice. Low risk cases were defined by pretransplant characteristics, using the model for end-stage liver disease (MELD) score, which predicts mortality on the waiting list, and the balance of risk (BAR) score, which takes into account recipient and donor factors. Other well-established risk factors were considered exclusion criteria to define the benchmark cohort. [13] [14] [15] [16] We selected 13 endpoints -to compute benchmark cutoffs based on their clinical relevance and reproducibility. These benchmark values may serve as reference for future studies and help assess worldwide results and trends in the field of LT.
METHODS

Center Selection and Data Sources
We screened countries on every continent for centers performing at least 50 cadaveric LT per year during the 5-year study period (2010) (2011) (2012) (2013) (2014) (2015) and holding a prospectively collected and audited database. The highest volume centers in the respective countries were selected and the final collaborative consortium included 17 centers: 11 from Europe, 5 from North America, and 1 from South America. No Asian center could be included due to the small number of available cadaveric grafts.
Study Population and Variables of Interest
Benchmark cases were identified in every center database. To define ''ideal'' LT cases, we considered the mortality risk of the patients on the waiting list as well as the donor/recipient match, and thus selected patients based on the MELD score and the BAR score. 17, 18 The MELD score is a scoring system widely used for prioritization of patients awaiting LT -based on serum levels of bilirubin and creatinine, and the international normalized ratio for prothrombin time -predicting the risk of mortality on the waiting list in patients with chronic liver diseases. [18] [19] [20] We selected only patients with a MELD score 20 at the time of transplantation, as patients with higher figures have been shown to display a increasing mortality risk. 20 The BAR score predicts post-LT mortality by including donor age, recipient MELD score, recipient age, retransplant status, the need for mechanical ventilation, and cold ischemia time. 17 Patients with a BAR score 9 present an ideal donor-recipient match with very low mortality risk, and this cutoff was thus included as a selection criteria for benchmark cases. 7, 17, 21 To further narrow the selection of the ''best cases,'' we excluded patients with acute liver failure, patients on mechanical ventilation at the time of surgery, and patients receiving a graft from donors after circulatory death (DCD). 13, 16, [22] [23] [24] In addition, special situations and technical difficulties impacting outcomes, such as recipient portal vein thrombosis, previous major abdominal surgery (hepato-biliary surgery and extensive colorectal surgery), partial graft implantation or retransplantation were excluded. 14, 15, 25 In summary, patients with a MELD score 20, a BAR score 9 and receiving a standard LT from a donor after brain death were selected as benchmark cases.
Comparative Cohorts
To compare outcomes from the benchmark cohort, we identified 2 higher risk groups. First, we considered a slightly higher risk group from the same centers and study period using identical selection criteria except for the next higher MELD score ranging from 21 to 30 points. Second, to test the applicability of the established benchmark criteria for the assessment of a single-center cohort, we selected one of the highest risk groups from one of the benchmark centers -that is, those receiving a second graft due to failure of the original graft -over the same study period.
Collected Data, Outcomes, and Follow-up Local investigators collected center-specific data, using a secure online data entry management system, including the following recipient and donor characteristics: age, MELD before LT, underlying liver disease and comorbidities, cold ischemia time, and a variety of postoperative events at 4 specific time points (discharge, 3, 6, and 12 mo).
The primary end-point was morbidity and mortality. To assess LT morbidity, we selected peri-and postoperative parameters with proven impact on outcomes and costs, namely duration of surgery, intraoperative blood transfusion, hospital and intensive care unit (ICU) stay, as well as post-LT complications. [26] [27] [28] A systematic and comprehensive classification of all postoperative complications was performed using the Clavien-Dindo grading system. This system ranks complications by severity according to their therapeutic consequences. 29, 30 Briefly, grade I and II complications are events requiring only bedside procedures or a need for pharmacologic treatments. Grade III complications require surgical, radiological, or endoscopic treatment. Grade IV complications are life-threatening complications requiring ICU care, while grade V complications correspond to death. Patients requiring a retransplantation were graded IVa. To get additional information on morbidity, we then measured the cumulative morbidity using the comprehensive complication index (CCI 1 ). 31, 32 The CCI 1 expresses morbidity on a continuous numeric scale from 0 (no complications) to 100 (death) by weighing all postoperative complications according to the Clavien-Dindo classification for their respective severity. 31 Since in LT, complications related to the biliary tract are the most common complications and responsible for major costs and morbidity, they were additionally analyzed separately. 33, 34 Statistical Analysis
Benchmark Metrics
Benchmark cutoffs were determined for 1-year mortality, retransplantations, and peri-and postoperative morbidity indicators including length of surgery (skin-to-skin time), intraoperative blood transfusions, renal replacement therapy after transplantation until discharge, length of ICU, and hospital stay (from day of transplantation until hospital discharge), patients with mild ( grade II) and severe (grade ! III) complications, biliary complications, hepatic artery thrombosis (HAT) and the CCI 1 at discharge, 3 months, 6 months, and at 1 year. Every outcome indicator listed above was defined in the study protocol to secure standardization in data collection among all centers. Of note, biliary complications were defined as every post-transplant event related to the biliary system such as leaks, bilioma, strictures or infection, and graded according to the Clavien-Dindo classification, and subsequently integrated in the CCI 1 formula. The median value for every indicator in each center was determined and the 75th percentile of all center-specific median values for a given indicator was considered the benchmark cutoff, as previously reported. 12 Thus, we opted for an equal count of every center in this study, regardless of differences in caseloads.
We conducted descriptive statistics for various intra-and postoperative parameters to characterize the patient population. Survival curves were compared by using the log rank test and linear regression analysis was performed for correlations. A value of P < 0.05 was considered statistically significant. Statistical analysis was performed using Stat 10.1 and SPSS, version 19.
RESULTS
Benchmark Cohort
Seventeen centers provided 7492 cases of LT over the 5-year study period. Approximately one quarter (27%, n ¼ 2024) were benchmark cases with a large variation among centers (range: 8% to 49%) (Fig. 1) .
Characteristics and outcomes in the benchmark cohort: Patients in the benchmark cohort displayed a median donor and recipient age of 55 (IQR: 43-67) and 57 (IQR: 50-62) years, respectively. Median MELD and BAR scores were 12 (IQR: 9-16) and 4 (IQR: 2-6), respectively. Underlying liver diseases included hepatocellular carcinoma (47.4%), hepatitis C (78.5%), alcoholic cirrhosis (26.5%), and hepatitis B (2%). The median graft preservation time was short with 7 hours cold storage (IQR: 6-9). The median duration of LT was 5 hours (IQR: 290-480) with low transfusion requirements [2U RBC (unit of red blood cell), IQR: 0-5]. Postoperative renal replacement therapy was performed in 6.6% of cases. Consistently, median length of ICU and hospital stay were short with 2 (1-5) and 13 (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) days, respectively. Overall 1-and 5-year patient survival-rates were 91.6% (actual survival) and 78.2% (actuarial survival), respectively. Post-LT complications, however, occurred frequently during the 1-year follow-up; the majority of patients (82%) presented at least 1 complication and 58% developed more than 1 complication. Overall, two-thirds (68.7%) of the patients developed mild complications ( grade II), while almost half (48.9%) experienced a severe complication requiring intervention (! grade III). Biliary complications occurred in 18.8% of the patients; the majority (57.7%) after hospital discharge. Accordingly, the overall median post-transplant morbidity index (CCI 1 ) increased over time from 20.9 at discharge (IQR: 0-34.6) to 26. 
Center-specific and Volume Effect on Outcomes
We recorded a significant variability in perioperative morbidity indicators among centers, namely median length of surgery (IQR: 4.9-8.1 h), median ICU (IQR: 1-8 d), and hospital stay (IQR: 6-24 d). The same applied to the CCI 1 from discharge (IQR: 0-51.7) to 1 year (IQR: 20.9-62.9). These results, however, did not correlate with the respective center volume. Interestingly, we noted that centers performing less benchmark cases; that is, higher proportion of more difficult cases, had less biliary complications in the benchmark cohort (Pearson R ¼ 0.68, P ¼ 0.002, Fig. 2 ).
Benchmark Values
The benchmark cutoffs, calculated as the 75th percentile of the medians of each center, served to indicate the best achievable results for each post-LT parameter (Tables 1 and 2 ). The benchmark for 1-year mortality and graft-loss are 9% and 11%, respectively. 
Higher MELD Cohort
In a next step, we compared outcomes in the benchmark cohort with sicker transplant recipients, displaying a MELD score ranging from 21 to 30 (median MELD 24, IQR: 22-27), but otherwise same selection criteria (Table 2 ). In this cohort (n ¼ 699), 1-year survival was similar to the benchmark cohort (88.7% vs 91.6%, P ¼ 0.154). Although morbidity increased, most outcome endpoints remained inside the benchmark cutoffs. Only intraoperative transfusion rates (5 U RBC vs 3 U RBC), patients with renal replacement therapy after LT (13.7% vs 3%), grade IV complications (24% vs 20%) and retransplantations (7.1% vs 4%) were outside the benchmark cutoffs. Cumulative post-LT morbidity, expressed by the CCI 1 at discharge and after 1 year, remained within the benchmark threshold (29.6 vs 29.6, and 39.7 vs 42.1).
Second Graft (Retransplantation) Cohort
To test the applicability of the benchmark thresholds in a high-risk group, we looked at 50 patients receiving a second transplantation due to graft failure at 1 center. The median MELD score in that group was 30 (IQR: 24-36) and the median BAR was 17 (IQR: [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Overall, 28% of retransplantations were performed in the first 2 weeks following primary LT, 34% between day 15 and the first year, and 38% thereafter. The main etiologies for a retransplantation were primary nonfunction in 26%, nonanastomotic biliary stenosis in 20%, hepatitis C recurrence in 16%, and hepatic artery thrombosis in 10% of cases. Except for the use of 1 DCD graft, all retransplantations were performed with whole grafts from donors after brain death (n ¼ 49). We observed a 30% reduction in 1st-year patient survival, when compared with the benchmark cutoffs (58% vs ! 88%), and all outcome parameters in the re-LT groups were unambiguously inferior to the benchmark cutoffs (Table 2) . For example, ICU-and hospital stays were twice as high (8 d 
DISCUSSION
This is the first attempt to quantify best possible outcomes after LT using an international cohort of well-defined benchmark cases, representing approximately 1 quarter of overall LTs. This analysis is crucial for conclusive comparisons among different groups of patients, centers, and over time. We chose a number of clinically relevant endpoints in this ''ideal'' LT cohort, disclosing an excellent 1-year survival, but with high postoperative morbidity, increasing significantly during the first year after LT. The outcome analysis of 2 higher LT cohorts illustrated the relevance of the benchmark values. LT belongs to one of the most successful therapies developed over the past half century rescuing many patients with almost certain short-term death to a close-to-normal quality of life and full function in the society. 7 The success of this complex procedure has emergedbesides center and team experience -through proper patient and donor selection, at the cost, however, of significant perioperative morbidity. 35 With an ever-increasing gap between need and organ supply, many groups have developed novel strategies to augment the number of available grafts such as living donation, donation after cardiac arrest, or the use of injured grafts, for example, fatty livers. This raises the question of how to evaluate these strategies, not only in terms of patient survival, but also by using more subtle morbidity endpoints with eventually financial burden. This study providesthrough a careful methodology -baseline values for various outcome indicators in ''ideal'' LT patients, a concept called ''benchmarking,'' and a new tool for comparisons with other LT patient groups or even competitive procedures.
The selection of benchmark patients was performed by a stepwise risk stratification. First, we selected patients with a BAR score 9 points since this threshold has been reported to have an increasing morbidity and length of hospital stay. 17, 21 Of note, the combination of high donor age (>40 yrs), high recipient age (>60 yrs), and prolonged cold ischemia (> 12 h) is in theory within the BAR 9 threshold. Second, we chose recipients with a MELD score 20, as we have shown inferior results at this cutoff. 36 Third, we excluded established risk factors such as retransplantation, portal vein thrombosis, acute liver failure, or high-risk donors to narrow the selection toward the optimal scenarios. 13, 14, 16 We did not consider additional cardiac, pulmonary, or connective tissue diseases of the recipient since these characteristics are less frequently captured in a prospective manner, and may lead to missing values.
We solely selected centers with a sufficient caseload, besides a well-mixed distribution around the world. We, however, made no restrictions regarding local strategies for graft preservation, implantation, and reperfusion techniques to be representative of the ''real world.'' Our first observation was the variation in the proportion of benchmark cases among centers, ranging from less than 10% to more than 40% (Fig. 1) . This difference likewise reflects how much risk centers are willing to take in terms of recipient and donor selection. One factor influencing this decision is the availability of donors, ranging from 8 to more than 45 donors per million population among the 17 participating centers. 37, 38 Low donation rates force LT centers to take more risk to serve accumulating very sick patients awaiting a graft. In support of this argument, we noted that higher donation rates were associated with a higher amount of benchmark cases (data not shown). Additionally, some centers in the cohort must deal with more than two-thirds of so-called ''extended criteria donors,'' the most frequent being fatty liver grafts, which obviously are associated with more risk. 39, 40 Thus, the methodology used for this study further validates the selection process identifying the ''benchmark cohort.' ' We confirmed excellent survival rates close to 90% in this low risk population, as documented in most national and regional registries, but the study revealed impressively high morbidity rates with many severe complications occurring all over the 1st year post-LT follow-up. Comparing these data with the results for benchmark cases in major hepatectomy, we see a significant higher morbidity rate in the benchmark LT cases. 12 For example, benchmark values in LT cases are 3 times higher for overall and 5 times higher for severe complications, compared with benchmark values in major hepatectomy cases ( 90% vs 31.2% and 58% vs 9.2%). These results further underline the need to select fine indicators of morbidity as endpoints for comparative studies, while mortality as endpoint appears too crude and with poor correlation with costs. 12, 32, 41 The main issue in reporting complications has been the absence of standardization in definition and severity grading of postoperative negative events, as well as the lack of a reproducible and ''easy-to-understand'' metric system. 42, 43 The Clavien-Dindo classification of complications -currently adopted in most areas of the world -ranks complications by severity based on their respective treatment. 29, 30 The subsequent development of the CCI 1 , integrating all recorded complications into a single formula providing an index ranging from 0 (no complication) to 100 (death), is a validated metric system for comparative studies. 32, [44] [45] [46] [47] [48] Together with other perioperative patient and cost-related outcome indicators, these morbidity tools were logically selected for establishing benchmark cutoffs. 43 Another controversial and inconsistently reported issue is the minimum length of postoperative follow-up to accurately assess morbidity. We previously identified a minimal follow-up of 3 months to adequately document morbidity after major liver resection. 12 Here looking at a procedure associated with dramatically higher morbidity, we could document that the minimal follow-up must cover 1 year, because major complications, mostly biliary, continued to rise between 6 and 12 months after transplantation. Also interestingly, mortality increased from 4% to 7% between 3 and 6 months, and further increased to 9% at 1 year. In contrast, almost all HAT occurred before hospital discharge; i.e. within 4 weeks; which appears to be a serious event, since all cases required a retransplantation (data not shown). Of note, we cannot exclude from our database that other clinically silent HAT may occur later after surgery.
We also looked at the impact of center-volume on morbidity and mortality rates in the benchmark cohort. We observed that centers with a higher proportion of benchmark cases, that is, performing mostly low risk cases, had more biliary complications. One explanation could be that centers performing higher proportion of complex cases may develop better skills in preventing or correcting biliary problems.
Validation of the benchmark cohort was performed using 2 comparative cohorts. First, we used a slightly higher risk group to test the ability of the benchmark analysis to quantify a minor increase in morbidity. Second, we used a singlecenter retransplant cohort to test the applicability of the benchmark cutoffs to quantify the magnitude of a more consequent increase in mortality and morbidity. In the first comparative group with slightly higher MELD scores (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , we failed to show any impact on mortality, but overall morbidity increased in this higher MELD group, with significantly higher need for intraoperative transfusion, postoperative renal replacement, and more grade IV complications. This analysis highlights differences, which have escaped to all previous reports, supporting a high sensitivity for benchmark thresholds. When considering the second comparative group, one of the highest risk groups from a single center, patients requiring a 2nd graft, the increase in morbidity becomes obvious covering all measured endpoints, and consequently quality of life of the patients, at least for the first year following surgery. This high morbidity probably has a massive effect on cost, as postoperative complications were found to be the most significant factors affecting direct and indirect costs. 39 Another important issue to secure quality in outcome research is the accuracy in capturing postoperative complications, which depends on prospective collection of data, optimally by an
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Benchmarks for Liver Transplantation independent observer and regular auditing. 49 While our study targeted those objectives, we observed variability in grade I complications among centers calling for suspicion of missing data. We therefore tested the impact of omitting grade I events for the CCI 1 . As shown in the inaugurating report on the CCI 1 , the contribution of grade I complications decrease exponentially with the occurrence of more severe complication (figure in supplementary material online, http://links.lww.com/SLA/B317). 32 Thus, considering high morbidity in the LT cohort, collecting grade I complications can be omitted in future studies with minimal consequence on outcome data.
Future possible applications of benchmarks could help to identify relevant performance metrics, and thus contribute to improve surgical care, techniques, and training (Table 3) . In this context, contrarily to suggestions that reporting on highly selected cases may cause risk-averse behavior or threats to innovation due to a fear of not being able to match results and consequently being blamed, 50, 51 we would argue that benchmarking rather offers new horizons. Benchmarking, as proposed here and in our previous work on major hepatectomy, 12 that is, following a strict methodology, offers reference values applicable somewhat universally, which is different from traditional comparisons, even when a heterogeneous group is risk adjusted. In our view, those comparisons are associated with 3 significant limitations. First, since no reference value is available, such studies provide only information related to the examined groups. Second, the lack of standardization in reporting weakens generalizability of most studies, which typically fail to provide convincing information on morbidity, and third understanding of the many risk adjustment methodologies is cumbersome for many clinicians. The concept of benchmarking, as reference values is simple, informative and thus likely to be adopted for many procedures. Benchmarking would, however, not replace major comprehensive databases like the American College of Surgeons National Surgical Quality Improvement Program, which best provide detailed outcome information on specific events on individual patients, who undergo specific interventions.
In conclusion, this multicentric study proposes 13 benchmark values, which may serve as reference to evaluate LT around the globe. Any patient or group of patients, who disclose an outcome fitting within the benchmark values, should be considered ''optimal'' results. Deviation from those values must of course be discussed with caution, and interpreted in the context of additional risk factors. Important subgroups of patients, for example those receiving a DCD graft or a second graft, may benefit from new benchmark studies targeting those specific populations. The next logical application of the current study may be to test how far is the outcome of marginal grafts or sicker recipients from benchmark values. Several of the authors currently select their cases to be presented at morbidity/mortality conference based on the benchmark cutoffs. We believe that this new concept of benchmarking, now also available for major liver resection and oesophagectomy, 12 ,52 may find wide acceptance in daily clinical practice and for future studies. Use benchmarks to assess the gap in morbidity and mortality with higher risk groups
Estimating and comparing costs Correlate morbidity in benchmark cases to costs to quantify financial burden in more complex cases Self-evaluation Select patients outside the benchmark CCI 1 value to be discussed at morbidity and mortality conferences Surgical training Define optimal teaching operations by selecting patients within benchmark criteria and thus establish minimal required teaching cases for a given center Patient quality-of-life Use benchmarks to quantitatively assess the negative impact of increased morbidity on quality-of-life in complex surgical procedures and selectively optimize postoperative patient care Implementation of innovative surgical strategies and techniques Select appropriate study candidates using benchmark criteria
Compare the results to the established benchmarks for validation Interdisciplinary comparisons
Comprehensively compare outcomes for a surgical procedure to those in other surgical fields by using benchmark values
